NRX Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Mar 14, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 14, 2025
NRXP$2.380.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statement of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| Years ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(25,126) | $(30,150) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 5 | 5 |
| Stock-based compensation | 486 | 387 |
| Common stock issued in exchange for services | 37 | — |
| Change in fair value of warrant liabilities | 1,657 | (20) |
| Change in fair value of convertible promissory notes | 2,654 | 2,707 |
| Loss on convertible notes redemptions | 1,278 | — |
| Expense for debt issuance costs due to fair value election on Anson Notes | 896 | — |
| Warrant issuance costs related to Alvogen termination | 1,336 | — |
| Convertible note default penalty | 849 | — |
| Non-cash settlement expense | — | 250 |
| Increases (decreases) in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 503 | 3,040 |
| Accounts payable | (5,217) | 2,655 |
| Accrued expenses and other liabilities | 10,005 | (531) |
| Net cash used in operating activities | (10,637) | (21,657) |
| CASH FLOWS FROM INVESTING ACTIVITIES | ||
| Purchase of computer equipment | — | (3) |
| Net cash used in investing activities | — | (3) |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Repayment of convertible note | (7,850) | (3,092) |
| Repayment of insurance loan | (725) | (943) |
| Expense for debt issuance costs due to fair value election on Anson Notes | (896) | — |
| Proceeds from issuance of insurance loan | 1,045 | 943 |
| Proceeds from Anson convertible notes, net of OID | 6,034 | — |
| Proceeds from liability classified warrants | 3,966 | — |
| Proceeds from issuance of Series A preferred stock and warrants issued in private placement, net of issuance costs | — | 1,171 |
| Proceeds from issuance of common stock and warrants, net of issuance costs | 4,884 | — |
| Proceeds from issuance of common stock and warrants issued in private placement, net of issuance costs | 1,027 | 8,122 |
| Net cash provided by financing activities | 7,485 | 6,201 |
| Net decrease in cash and cash equivalents | (3,152) | (15,459) |
| Cash and cash equivalents at beginning of year | 4,595 | 20,054 |
| Cash and cash equivalents at end of year | $1,443 | $4,595 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $374 | $885 |
| Cash paid for taxes | $— | $— |
| Non-cash investing and financing activities | ||
| Issuance of common stock as principal and interest repayment for convertible notes | $4,585 | $982 |
| Issuance of common stock warrants as offering costs | $188 | $75 |
| Issuance of common stock for settlement of accrued liability | $— | $250 |
| Conversion of Series A preferred stock into common stock | $3 | $— |
DECEMBER 31, 2024 AND 2023
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.